...
首页> 外文期刊>Clinical and experimental allergy : >Molecular diagnosis in allergy.
【24h】

Molecular diagnosis in allergy.

机译:过敏的分子诊断。

获取原文
获取原文并翻译 | 示例

摘要

Development and progress made in the field of recombinant allergens have allowed for the development of a new concept in allergy diagnosis, molecular diagnosis (MD), which makes it possible to identify potential disease-eliciting molecules. Microarray-based testing performed with a small amount of serum sample enables clinicians to determine specific-IgE antibodies against multiple recombinants or purified natural allergen components. Performance characteristics of allergens so far tested are comparable with current diagnostic tests, but have to be confirmed in larger studies. The use of allergen components and the successful interpretation of test results in the clinic require some degree of knowledge about the basis of allergen components and their clinical implications. Allergen components can be classified by protein families based on their function and structure. This review provides a brief overview of basic information on allergen components, recombinants or purified, currently available or soon to become commercially available in ImmunoCAP or ISAC systems, including names, protein family and function. Special consideration is given to primary or species-specific sensitization and possible cross-reactivity, because one of the most important clinical utility of MD is its ability to reveal whether the sensitization is genuine in nature (primary, species-specific) or if it is due to cross-reactivity to proteins with similar protein structures, which may help to evaluate the risk of reaction on exposure to different allergen sources. MD can be a support tool for choosing the right treatment for the right patient with the right timing. Such information will eventually give clinicians the possibility to individualize the actions taken, including an advice on targeted allergen exposure reduction, selection of suitable allergens for specific immunotherapy, or the need to perform food challenges. Nevertheless, all in vitro tests should be evaluated together with the clinical history, because allergen sensitization does not necessarily imply clinical responsiveness.
机译:重组变应原领域的发展和进步使得在变态反应诊断中新概念的发展成为可能,即分子诊断(MD),这使得鉴定潜在的引起疾病的分子成为可能。使用少量血清样品进行的基于微阵列的测试使临床医生能够确定针对多种重组体或纯化的天然过敏原成分的特异性IgE抗体。迄今为止测试的变应原的性能特征与当前的诊断测试相当,但必须在更大的研究中得到证实。过敏原成分的使用和临床测试结果的成功解释要求对过敏原成分的基础及其临床意义有一定程度的了解。过敏原成分可以根据其功能和结构按蛋白质家族分类。这篇综述简要概述了ImmunoCAP或ISAC系统中目前可用或即将商业化的过敏原成分,重组或纯化的基本信息,包括名称,蛋白质家族和功能。特别要注意原发性或物种特异性致敏作用以及可能的交叉反应性,因为MD最重要的临床用途之一是它能够揭示敏化性质是真正的(主要的,特定于物种的)敏化能力还是由于与具有相似蛋白质结构的蛋白质具有交叉反应性,因此可能有助于评估暴露于不同变应原来源时的反应风险。 MD可以成为在正确的时机为正确的患者选择正确治疗方法的支持工具。这些信息最终将使临床医生有可能对所采取的措施进行个性化处理,包括针对减少有针对性的过敏原的建议,针对特定免疫疗法选择合适的过敏原或进行食物挑战的需求。但是,应将所有体外测试与临床病史一起进行评估,因为变应原致敏并不一定意味着临床反应性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号